Spots Global Cancer Trial Database for A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Official Title: A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer
Study ID: NCT04916002
Study Description
Brief Summary: The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: * How many participants' cancers respond to vidutolimod together with cemiplimab? * Is vidutolimod together with cemiplimab safe and well-tolerated? * How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have a follow-up visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
Detailed Description: Former Sponsor Checkmate Pharmaceuticals
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama, Birmingham, Alabama, United States
City of Hope, Duarte, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
University of California, Los Angeles, California, United States
GenesisCare USA, Jacksonville, Florida, United States
Orlando Health Cancer Institute, Orlando, Florida, United States
University of Iowa, Iowa City, Iowa, United States
Norton Cancer Institute, Louisville, Kentucky, United States
VA Maryland Health Care System, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Dartmouth Clinical Trial Office, Lebanon, New Hampshire, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
East Carolina University, Greenville, North Carolina, United States
Ohio State University, Columbus, Ohio, United States
OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Oncology Consultants, Houston, Texas, United States
University of Utah Huntsman Cancer Center, Salt Lake City, Utah, United States
University of Washington, Seattle, Washington, United States
St. Vincent's Hospital, Darlinghurst, New South Wales, Australia
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Peter MacCallum Cancer Centre (PMCC) and The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Contact Details
Name: Clinical Trial Management
Affiliation: Regeneron Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
